KALA BIO’s (KALA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of KALA BIO (NASDAQ:KALA) in a report issued on Friday morning,Benzinga reports. They currently have a $15.00 target price on the stock.

KALA BIO Price Performance

KALA stock opened at $4.24 on Friday. KALA BIO has a 52-week low of $4.01 and a 52-week high of $11.20. The business has a fifty day moving average of $7.42 and a two-hundred day moving average of $6.78. The stock has a market cap of $25.83 million, a price-to-earnings ratio of -0.34 and a beta of -1.70. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Friday, March 28th. The company reported ($1.74) EPS for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.54. As a group, research analysts anticipate that KALA BIO will post -10.84 earnings per share for the current year.

Hedge Funds Weigh In On KALA BIO

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in KALA BIO by 28.4% in the fourth quarter. Geode Capital Management LLC now owns 47,642 shares of the company’s stock valued at $331,000 after purchasing an additional 10,526 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of KALA BIO by 10.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 178,934 shares of the company’s stock valued at $1,242,000 after buying an additional 16,271 shares in the last quarter. AIGH Capital Management LLC purchased a new stake in shares of KALA BIO in the 4th quarter valued at $842,000. SR One Capital Management LP lifted its stake in KALA BIO by 35.0% during the 4th quarter. SR One Capital Management LP now owns 598,940 shares of the company’s stock worth $4,157,000 after acquiring an additional 155,279 shares in the last quarter. Finally, Silverarc Capital Management LLC acquired a new position in KALA BIO during the 4th quarter worth about $1,604,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.